Treatment for allergy and method of composition thereof

Claim 3

The method of claim 1 wherein in formula (I) one of Z 1 and Z 2 is a 5-(1-R) tetrazolyl or a 5-(2-R)tetrazolyl group wherein R is hydrogen or alkyl having 1 to 6 carbon atoms, and the other is selected from the group consisting of carboxy, 5-(1-R)tetrazolyl and 5-(2-R)tetrazolyl as defined; and Z 2 is also selected from hydrogen, nitro, cyano, chlorine, bromine, acyl, alkyl or alkoxy wherein the "alkyl" moiety of each of the acyl, alkyl and alkoxy groups has 1 to 6 carbon atoms; together with salts, and when Z 1 or Z 2 is carboxy, esters and amides thereof as defined in claim 1.

Claim 4

The method of claim 1 wherein in formula (I) one of Z 1 and Z 2 is 5-tetrazolyl and the other is carboxy, together with salts of said compounds.

Claim 5

The method of claim 1 wherein in formula (I) Z 2 is hydrogen or is a substituent as defined therein in the 7-position.

Claim 6

The method of claim 1 wherein in formula (I) one of Z 1 and Z 2 is 5-tetrazolyl and the other is carboxy or 5-tetrazolyl together with salts of said compounds.

Claim 7

The method of claim 4 wherein in formula (I) Z 2 is in the 7-position.

Claim 8

The method of claim 6 wherein Z 2 is propoxycarbonyl, butyl or bromine.

Claim 9

The method of claim 1 wherein the tricyclic compound is selected from: 5-(7-propoxycarbonyl-2-fluorenone)tetrazole; 5-(7-butyl-2-fluorenone)tetrazole; 5-(7-bromo-2-fluorenone)tetrazole; and pharmaceutically acceptable salts thereof.

Claim 10

The method of claim 1 wherein the prophylactically effective dose is from 2 μg to 100 mg. per kilogram bodyweight of the mammal.

Claim 11

The method of claim 1 comprising administration into the lung of the mammal of a dose of 20 μg to 0.5 mg of said compound for the treatment or prophylaxis of allergic asthma.

Claim 12

The method of claim 1 wherein administration is effected by the oral route.

Claim 13

The method of claim 1 wherein the anti-allergic dose is from 1 to 50 mg of said compound of said compound of formula (I) per kilogram bodyweight of the mammal.

Claim 14

The method of claim 1 wherein said condition is allergic asthma.

Claim 15

The method of inhibiting the symptoms of conjunctivities in a mammal having conjunctivitis which comprises administration to said mammal of a prophylactically effective non-toxic amount of a compound of formula I as defined in claim 1.

Claim 16

The method of inhibiting the symptoms of urticaria in a mammal having urticaria which comprises administration to said mammal of a prophylactically effective non-toxic amount of a compound of formula I as defined in claim 1.

Claim 17

The method of inhibiting the symptoms of eczema in a mammal having eczema which comprises administration to said mammal of a prophylactically effective non-toxic amount of a compound of formula I as defined in claim 1.

Claim 18

A pharmaceutical composition suitable for administration to a mammal to inhibit the symptoms of asthma or allergic rhinitis which comprises a prophylactically effective non-toxic amount of a compound of formula (I) ##STR10## wherein one of Z 1 and Z 2 is a 5-(1-R)tetrazolyl or a 5-(2-R) tetrazolyl group in which R is hydrogen or alkyl having 1 to 6 carbon atoms, and the other is selected from the group consisting of carboxy, 5-I1-R)tetrazolyl and 5-(2-R)tetrazolyl as defined, provided that when Z 2 is 5-(1-R)tetrazolyl or 5-(2-R)tetrazolyl then Z 1 is carboxy and Z 2 is also selected from the group consisting of hydrogen, nitro, cyano, halogen, alkylsulphinyl, alkylsulphonyl, acyl, alkyl or alkoxy wherein the "alkyl" moiety of each of the acyl, alkyl, alkoxy, alkylsulphinyl, and alkylsulphonyl groups has 1 to 6 carbon atoms; together with salts and when Z 1 or Z 2 is carboxy, alkyl esters having 1 to 6 carbons and unsubstituted amides or amides substituted by one or two alkyl groups having 1 to 6 carbons of said compounds of formula (I) in association with a pharmaceutically acceptable carrier therefor.

Claim 19

A pharmaceutical composition suitable for administration to a mammal to inhibit the symptoms of asthma or allergic rhinitis which comprises a prophylactically effective non-toxic amount of a compound of formula (I) ##STR10## wherein one of Z 1 and Z 2 is a 5-(1-R)tetrazolyl or a 5-(2-R) tetrazolyl group in which R is hydrogen or alkyl having 1 to 6 carbon atoms, and the other is selected from the group consisting of carboxy, 5-I1-R)tetrazolyl and 5-(2-R)tetrazolyl as defined, provided that when Z 2 is 5-(1-R)tetrazolyl or 5-(2-R)tetrazolyl then Z 1 is carboxy and Z 2 is also selected from the group consisting of hydrogen, nitro, cyano, halogen, alkylsulphinyl, alkylsulphonyl, acyl, alkyl or alkoxy wherein the "alkyl" moiety of each of the acyl, alkyl, alkoxy, alkylsulphinyl, and alkylsulphonyl groups has 1 to 6 carbon atoms; together with salts and when Z 1 or Z 2 is carboxy, alkyl esters having 1 to 6 carbons and unsubstituted amides or amides substituted by one or two alkyl groups having 1 to 6 carbons of said compounds of formula (I) in association with a pharmaceutically acceptable carrier therefor.

Claim 20

The composition as claimed in claim 17 wherein in formula (I) one of Z 1 and Z 2 is a 5-(1-R)tetrazolyl or a 5-(2-R)tetrazolyl group wherein R is hydrogen or alkyl having 1 to 6 carbon atoms, and the other is selected from the group consisting of carboxy, 5-(1-R)tetrazolyl and 5-(2-R)tetrazolyl as defined; and Z 2 is also selected from hydrogen, nitro, cyano, chlorine, bromine, acyl, alkyl or alkoxy wherein the "alkyl" moiety of each of the acyl, alkyl and alkoxy groups has 1 to 6 carbon atoms; together with salts, and when Z 1 or Z 2 is carboxy, esters and amides thereof as defined in claim 17.

Claim 21

The composition of claim 17 wherein in formula (I) one of Z 1 and Z 2 is 5-tetrazolyl and the other is carboxy, together with salts of said compounds.

Claim 22

The composition of claim 17 wherein in formula (I) Z 2 is hydrogen or is a substituent as defined therein in the 7-position.

Claim 23

The composition of claim 20 wherein in formula (I) one of Z 1 and Z 2 is 5-tetrazolyl and the other is carboxy together with salts of said compounds.

Claim 24

The composition of claim 17 wherein in formula (I) Z 2 is in the 7-position.

Claim 25

The composition of claim 17 comprising a compound selected from; 5-(7-propoxycarbonyl-2-fluorenone)tetrazole; 5-(7-butyl-2-fluorenone)tetrazole; 5-(7-bromo-2-fluorenone)tetrazole; and pharmaceutically acceptable salts thereof.

Claim 26

The composition of claim 17 wherein the pharmaceutically acceptable salt is selected from a sodium, potassium, magnesium, calcium or ammonium salt and a salt with an organic base.

Claim 27

The composition of claim 17 wherein the composition is in the form of a discrete dosage unit selected from a tablet, capsule, lozenge and sachet, each unit containing from 50 to 500 mg. of said tricyclic compound.

Claim 28

The composition of claim 18 wherein said tricyclic compound is in the form of a powder adapted for pulmonary administration.

Claim 29

The composition of claim 26 in the form of a self propelling aerosol composition comprising said tricyclic compound dispersed in a liquid propellant in a sealed valved container.

Claim 30

The composition of claim 26 wherein said powder is incorporated in a capsule suitable for use in an inhalation device.

Claim 31

The composition of claim 22 wherein Z 2 is selected from butyl, bromine and propoxycarbonyl.

Claim 32

The composition suitable for administration to a mammal to inhibit the symptoms of conjunctivitis urticaria or eczema which comprises a prophylactically effective non-toxic amount of a compund of formula (I) as defined in claim 1.